Oryzon Genomics SA (ORY) — Cash Flow-to-Debt Ratio
Oryzon Genomics SA (ORY) has a Cash Flow-to-Debt Ratio of -0.09x as of June 2023, meaning its operating cash flow of €-2.41 Million could theoretically repay 0% of its total liabilities (€26.10 Million) in one year. See Oryzon Genomics SA (ORY) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Oryzon Genomics SA Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Oryzon Genomics SA across 13 annual periods. Also explore Oryzon Genomics SA equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Oryzon Genomics SA (2013–2025)
Year-by-year debt coverage analysis for Oryzon Genomics SA. For market capitalisation and broader financial context, see Oryzon Genomics SA (ORY) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.09x | €-2.36 Million | €26.68 Million | ▲ +66.4% |
| 2024 | -0.26x | €-5.69 Million | €21.67 Million | ▼ -1047.2% |
| 2023 | -0.02x | €-574.96K | €25.13 Million | ▲ +61.4% |
| 2022 | -0.06x | €-1.85 Million | €31.13 Million | ▲ +60.5% |
| 2021 | -0.15x | €-3.63 Million | €24.12 Million | ▲ +43.3% |
| 2020 | -0.27x | €-4.82 Million | €18.18 Million | ▲ +99.5% |
| 2019 | -49.56x | €-3.93 Million | €79.38K | ▼ -166006.5% |
| 2018 | -0.03x | €-666.09K | €22.33 Million | ▲ +83.1% |
| 2017 | -0.18x | €-4.71 Million | €26.61 Million | ▲ +4.6% |
| 2016 | -0.19x | €-5.01 Million | €27.02 Million | ▼ -565.5% |
| 2015 | 0.04x | €523.14K | €13.14 Million | ▼ -96.0% |
| 2014 | 1.00x | €12.13 Million | €12.16 Million | ▲ +15.4% |
| 2013 | 0.86x | €12.13 Million | €14.04 Million | — |